Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301).

NCT01076010 is registered in ClinicalTrials.gov with AVEO Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01076010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01076010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301).
Lead sponsor
AVEO Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
July 31, 2014
Enrollment
277 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma